NHGRI Intramural Genomic Data Sharing Plan Form (Basic Study Information) Version 2020-10-16

Provide the information listed below.					
Checklist of required documents:					
□Institutional Certifications					
NHGRI Intramural Genomic Data Sharing Plan (this form)					
□Routing Sheet (see last page)					
PART I – Principal Investigator (PI) and Funding Information					
PI name:	PI e-mail:				
PI institution and branch:					
PI assistant/submitter name:	PI assistant/submitter e-mail:				
Do you have an eRA Commons account?	\Box Yes \Box No				
If YES, go to the next field.					
If NO, register at https://commons.era.nih.gov/commons/registration/registrationInstructions.jsp.					
NIH Grant or Contract number:	NIH Protocol number:				
NIH Institutes/Centers supporting the study:					
PART II – Study Registration Information					
Study title:					
Is this a multi-center study?	□ Yes □ No				
If YES, list participating sites:					
Data will be submitted (choose one):	Data to be released will meet the timeframes specified in				
\Box Within 3 months of last data generated or last clinical vi	the NHGRI Guidance for Data Submission and Data				
□ Data will be submitted by batches over Study Timeline (
based on clinical trial enrollment benchmarks). Specify:					
based on enniear that enronment benefiniarks). Speerry.	If NO , describe the data release timeline:				

Target data delivery dat	e (VVVV_MM	י(תמ	•	Target public release date (YYY)	V_MM_DD):
Target data delivery date (YYYY-MM-DD):		Target public Telease date (TTTT-MM-DD).			
Estimated # of bytes of	data to be de	eposited:		Estimated # of study participan	ts:
The individual-level data are to be made available through:		□ Unrestricted Access	□ Controlled Access		
Are you requesting an Alternative Data Sharing Plan for samples that cannot be shared through a public database or repository? If YES, complete the Request for an Alternative Data Sharing Plan □ Yes □ No form in its entirety and attach it to this document. If NO, list all submission locations: □ □ □ □					
□ AnVIL □ GEO □ dbVar	dbGaP dbSNP Sequence F	□ GenBank □ ClinVar Read Archive (SR	Databa	Organism ase (specify):	\Box Other (list all):

	PART III – St	tudy Description					
Study type(s) (e.g. collection, longitudinal, case-control, case set, control set, parent-offspring trios, cohort):							
Samples genotyped/sequenced (check all data types expected for this study).							
Note that sufficient phenotypic information should be submitted to replicate the aims of the study.							
Species □Human Data □Non-Human Data	General □Individual Phenotype □Individual Genotype	Sample Types □Germline □Tumor/Normal	Array Data □SNP Array □Expression Array				
Sample Collection Prospective Sample Existing (Legacy)	 Individual Sequencing Supporting Documents Metagenomic Proteomic/Metabolomic 	□DNA □RNA □Mitochondria □Microbiome	☐ Methylation Array ☐ Other (specify):				
Phenotype □Individual-level Data □Aggregate Data □N/A- no human data	□Images □Other (specify):	□From Repository □Other (specify):					
Genotypes Array derived Genotypes CNV calls from microarray CNV calls derived from Sequencing Genotype calls derived from Sequencing Somatic SNV (.MAF) Array CGH CNVs Other (specify):	Sequencing Whole Genome Targeted Genome Targeted Exome Whole Transcriptome Targeted Transcriptome Epigenomic Marks Sanger 16S rRNA Other (specify):	Analyses Association/Linkage Results Array derived Expression RNA Seq derived Expression Array derived Methylation Other (specify):	Describe other data that is anticipated to be shared:				

Note: If you are not submitting human data, proceed to Part VII - Intramural Routing Sheet

PART IV – Policy

Do you have an Institutional Certification(s) (IC) to submit these data?

The IC will include the Data Use Limitations (DUL), which are based on the informed consent given by each research subject. For every research subject, his/her corresponding data will be tagged with the appropriate DUL. Each study may have multiple DULs, based on the informed consent of all the participants in the study.

If Yes, send the IC(s) to the NHGRI Genomic Program Administrator (GPA) along with this document. If NO, obtain the IC from your Institutional Signing Official. dbGaP requires that the sponsoring NIH Institute/Center verifies that this certification has been met. A description of the requirements for the IC and an example may be found in the <u>Points to Consider for Institutions and Institutional Review Boards in Submission and Secondary Use of Human</u> <u>Genomic Data under the National Institutes of Health Genomic Data Sharing Policy</u> guide.

 \Box Yes \Box No

PART V – Acknowledgment Statement(s)

The submitting PI should provide specific points that should be included in the Acknowledgment, such as sources of support or collaborators who provided subjects or samples. NIH support must be specifically acknowledged by including the grant or IRB number. Consider citing a publication that comprehensively describes the origin of the dataset.

The suggested Acknowledgment Statement to accompany the dataset is: (if needed, attached additional documentation)

PART VI - Request for an Exception for Samples Lacking Explicit Consent for Future Research Use and Broad Sharing

NHGRI expects all human data generated by NHGRI-supported research will be derived from specimens or cell lines for which **explicit consent** for future research use and broad sharing can be documented. NHGRI recognizes that not all studies are able to meet this expectation. For these studies an exception may be requested with strong justification.

Are you requesting an Exception for samples that lack explicit consent for future research use and broad data sharing?

If NO, proceed to Part VII.

If YES, complete the rest of this section. You must include a written justification for the request in part 3 below.

- 1. Name and Description of human specimen(s) or cell lines(s):
- 2. Rationale for the proposed use (choose one or more options below).
 - □ Specimens are from study populations that restrict or limit broad data sharing and future research use (e.g., participants from recognized tribal nations) request an Alternative Data Sharing Plan (Part VII).
 - □ Specimens or cell lines are highly studied, and this research will replace or augment existing data.
 - □ The research requires benchmarking of significantly improved, modified protocols generated using existing, standardized cell lines or specimens.
 - $\hfill\square$ Other you must provide a strong justification for the exception.
- 3. Justification for the reason selected above (limit to 1-2 paragraphs. If needed, attach additional documentation). Must include:
 - i. An explanation as to why other existing resources or new biosamples with appropriate consent cannot be obtained or used.
 - ii. An explanation as to why this biosample uniquely addresses the needs of the field.

PART VII – Intramural Routing Sheet					
If filled out electronically, the "Fill and Sign" tool can be used to electronically sign this document.					
Investigator (Print name)	Date				
Investigator (Signature)					
NHGRI Bioethics Core (Concurrence/Signature) If not applicable:	Date				
 OHSRP exemption determination (Please attach to this document) NHGRI Bioethics Core concurrence not applicable 					
Branch Chief (Print Name)	Date				
Branch Chief (Signature)					
Scientific Director/Designee (Print Name)	Date				
Scientific Director/Designee (Signature)					
Genomic Data Sharing Program Administrator (GPA) (Print Name)	Date				
Genomic Data Sharing Program Administrator (GPA) (Signature)					
Date registered in dbGaP:					
Director approval only if an Alternative Data Sharing Plan is requested					
NHGRI Director (Print Name)	Date				
NHGRI Director (Signature)					